TAKEDA TNP-470 FOR KAPOSI's SARCOMA IN PHASE I TRIAL
Executive Summary
TAKEDA TNP-470 FOR KAPOSI's SARCOMA IN PHASE I TRIAL, National Cancer Institute researcher James Pluda, MD, said May 16 at the American Society of Clinical Oncology's annual meeting in Dallas. To date, there have been no objective clinical responses to the angiogenesis inhibitor, Pluda reported, although there has been evidence of biological activity and the drug has been well tolerated. The study is being conducted by NCI and FDA's Center for Biologics Evaluation & Research.